Potential Benefits of Neoadjuvant Chemotherapy in Clinically Node-Positive Luminal Subtype(−) Breast Cancer

PURPOSE: Neoadjuvant chemotherapy (NAC) is less effective for luminal breast cancer because luminal breast cancer has a lower rate of pathological complete response (pCR) after NAC than human epidermal growth factor receptor 2 (HER2)-type and triple-negative breast cancer (TNBC). We investigated the...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Breast Cancer
Autors principals: Kim, Hyung Suk, Yoo, Tae Kyung, Park, Woo Chan, Chae, Byung Joo
Format: Artigo
Idioma:Inglês
Publicat: Korean Breast Cancer Society 2019
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6769389/
https://ncbi.nlm.nih.gov/pubmed/31598341
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4048/jbc.2019.22.e35
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars